<!DOCTYPE html>
<html>
<head>
<meta http-equiv="X-UA-Compatible" content="IE=Edge" />
<meta charset="utf-8" />
</head>

<body style="margin: 0;">

<div id="p193" style="overflow: hidden; position: relative; background-color: white; width: 1210px; height: 935px;">
<style class="shared-css" type="text/css" >
.t {
	transform-origin: bottom left;
	z-index: 2;
	position: absolute;
	white-space: pre;
	overflow: visible;
	line-height: 1.5;
}
.text-container {
	white-space: pre;
}
@supports (-webkit-touch-callout: none) {
	.text-container {
		white-space: normal;
	}
}
</style>
<style type="text/css" >

#t1_193{left:35px;bottom:24px;letter-spacing:-0.34px;word-spacing:0.13px;}
#t2_193{left:306px;bottom:30px;}
#t3_193{left:313px;bottom:24px;letter-spacing:0.16px;}
#t4_193{left:346px;bottom:30px;}
#t5_193{left:351px;bottom:24px;letter-spacing:-0.16px;word-spacing:-0.22px;}
#t6_193{left:517px;bottom:30px;}
#t7_193{left:524px;bottom:24px;letter-spacing:-0.28px;word-spacing:-0.09px;}
#t8_193{left:288px;bottom:860px;letter-spacing:0.11px;word-spacing:-0.55px;}
#t9_193{left:288px;bottom:829px;letter-spacing:0.27px;word-spacing:-0.69px;}
#ta_193{left:1115px;bottom:27px;letter-spacing:0.23px;}
#tb_193{left:35px;bottom:777px;letter-spacing:0.15px;word-spacing:0.04px;}
#tc_193{left:35px;bottom:754px;letter-spacing:0.22px;word-spacing:-0.03px;}
#td_193{left:337px;bottom:754px;}
#te_193{left:353px;bottom:754px;letter-spacing:0.22px;word-spacing:-0.03px;}
#tf_193{left:403px;bottom:761px;letter-spacing:-0.01px;}
#tg_193{left:427px;bottom:754px;letter-spacing:0.16px;word-spacing:0.03px;}
#th_193{left:35px;bottom:731px;letter-spacing:0.13px;word-spacing:0.05px;}
#ti_193{left:35px;bottom:707px;letter-spacing:0.13px;word-spacing:0.06px;}
#tj_193{left:35px;bottom:684px;letter-spacing:0.14px;word-spacing:-0.05px;}
#tk_193{left:35px;bottom:661px;letter-spacing:0.17px;word-spacing:0.02px;}
#tl_193{left:35px;bottom:638px;letter-spacing:0.11px;word-spacing:0.07px;}
#tm_193{left:540px;bottom:638px;}
#tn_193{left:557px;bottom:638px;}
#to_193{left:35px;bottom:614px;letter-spacing:0.36px;}
#tp_193{left:66px;bottom:622px;letter-spacing:-0.01px;}
#tq_193{left:35px;bottom:575px;letter-spacing:0.17px;word-spacing:0.01px;}
#tr_193{left:35px;bottom:552px;letter-spacing:0.14px;word-spacing:0.04px;}
#ts_193{left:35px;bottom:529px;letter-spacing:0.15px;word-spacing:0.04px;}
#tt_193{left:35px;bottom:506px;letter-spacing:0.01px;word-spacing:0.41px;}
#tu_193{left:35px;bottom:482px;letter-spacing:0.13px;word-spacing:0.05px;}
#tv_193{left:35px;bottom:459px;letter-spacing:0.13px;word-spacing:0.06px;}
#tw_193{left:335px;bottom:467px;letter-spacing:0.1px;}
#tx_193{left:380px;bottom:459px;letter-spacing:0.21px;word-spacing:-0.02px;}
#ty_193{left:35px;bottom:436px;letter-spacing:0.09px;word-spacing:0.21px;}
#tz_193{left:35px;bottom:413px;letter-spacing:0.07px;word-spacing:0.23px;}
#t10_193{left:35px;bottom:390px;letter-spacing:0.16px;word-spacing:0.02px;}
#t11_193{left:35px;bottom:366px;letter-spacing:0.1px;word-spacing:0.09px;}
#t12_193{left:35px;bottom:343px;letter-spacing:0.11px;word-spacing:0.07px;}
#t13_193{left:35px;bottom:320px;letter-spacing:0.08px;word-spacing:0.38px;}
#t14_193{left:35px;bottom:297px;letter-spacing:0.24px;}
#t15_193{left:98px;bottom:304px;}
#t16_193{left:35px;bottom:256px;letter-spacing:0.1px;word-spacing:0.08px;}
#t17_193{left:35px;bottom:233px;letter-spacing:0.14px;word-spacing:0.05px;}
#t18_193{left:35px;bottom:210px;letter-spacing:0.11px;word-spacing:0.07px;}
#t19_193{left:35px;bottom:187px;letter-spacing:0.03px;}
#t1a_193{left:112px;bottom:194px;}
#t1b_193{left:158px;bottom:187px;letter-spacing:-0.04px;word-spacing:0.58px;}
#t1c_193{left:35px;bottom:163px;letter-spacing:0.07px;word-spacing:0.11px;}
#t1d_193{left:35px;bottom:140px;word-spacing:1px;}
#t1e_193{left:249px;bottom:148px;letter-spacing:0.12px;}
#t1f_193{left:317px;bottom:140px;letter-spacing:0.09px;word-spacing:0.1px;}
#t1g_193{left:35px;bottom:117px;letter-spacing:0.1px;word-spacing:0.09px;}
#t1h_193{left:35px;bottom:94px;letter-spacing:0.1px;}
#t1i_193{left:98px;bottom:101px;letter-spacing:0.06px;}
#t1j_193{left:165px;bottom:94px;letter-spacing:0.17px;word-spacing:0.02px;}
#t1k_193{left:35px;bottom:71px;letter-spacing:0.06px;word-spacing:0.4px;}
#t1l_193{left:618px;bottom:777px;letter-spacing:0.09px;word-spacing:0.09px;}
#t1m_193{left:618px;bottom:754px;letter-spacing:0.01px;word-spacing:1.38px;}
#t1n_193{left:764px;bottom:761px;letter-spacing:0.12px;}
#t1o_193{left:831px;bottom:754px;letter-spacing:0.22px;word-spacing:-0.03px;}
#t1p_193{left:618px;bottom:731px;letter-spacing:0.21px;word-spacing:-0.02px;}
#t1q_193{left:1146px;bottom:738px;letter-spacing:-0.01px;}
#t1r_193{left:618px;bottom:690px;letter-spacing:0.12px;word-spacing:0.07px;}
#t1s_193{left:618px;bottom:667px;letter-spacing:0.22px;word-spacing:-0.03px;}
#t1t_193{left:792px;bottom:667px;letter-spacing:0.13px;word-spacing:0.06px;}
#t1u_193{left:618px;bottom:645px;letter-spacing:0.04px;word-spacing:-0.94px;}
#t1v_193{left:618px;bottom:622px;letter-spacing:0.11px;word-spacing:0.08px;}
#t1w_193{left:618px;bottom:599px;letter-spacing:0.17px;word-spacing:0.02px;}
#t1x_193{left:618px;bottom:575px;letter-spacing:0.09px;word-spacing:-0.31px;}
#t1y_193{left:1002px;bottom:583px;letter-spacing:-0.01px;}
#t1z_193{left:1025px;bottom:575px;letter-spacing:0.24px;word-spacing:-0.05px;}
#t20_193{left:618px;bottom:552px;letter-spacing:0.11px;word-spacing:-0.47px;}
#t21_193{left:618px;bottom:529px;letter-spacing:0.1px;word-spacing:0.08px;}
#t22_193{left:977px;bottom:536px;letter-spacing:0.1px;}
#t23_193{left:618px;bottom:487px;letter-spacing:0.22px;word-spacing:-0.03px;}
#t24_193{left:618px;bottom:463px;letter-spacing:0.15px;word-spacing:-0.33px;}
#t25_193{left:618px;bottom:440px;letter-spacing:0.27px;}
#t26_193{left:658px;bottom:440px;letter-spacing:0.2px;word-spacing:-0.01px;}
#t27_193{left:618px;bottom:416px;letter-spacing:0.16px;word-spacing:-0.79px;}
#t28_193{left:918px;bottom:416px;letter-spacing:0.15px;word-spacing:0.04px;}
#t29_193{left:618px;bottom:393px;letter-spacing:0.14px;word-spacing:-0.56px;}
#t2a_193{left:618px;bottom:370px;letter-spacing:0.09px;word-spacing:0.1px;}
#t2b_193{left:618px;bottom:330px;letter-spacing:0.02px;word-spacing:0.39px;}
#t2c_193{left:618px;bottom:308px;letter-spacing:0.14px;word-spacing:0.05px;}
#t2d_193{left:618px;bottom:284px;letter-spacing:0.09px;word-spacing:0.1px;}
#t2e_193{left:926px;bottom:292px;letter-spacing:-0.01px;}
#t2f_193{left:950px;bottom:284px;letter-spacing:0.08px;word-spacing:0.11px;}
#t2g_193{left:618px;bottom:261px;letter-spacing:0.12px;word-spacing:0.06px;}
#t2h_193{left:618px;bottom:238px;letter-spacing:0.08px;word-spacing:0.11px;}
#t2i_193{left:618px;bottom:215px;letter-spacing:0.07px;word-spacing:0.11px;}
#t2j_193{left:618px;bottom:192px;letter-spacing:0.21px;word-spacing:-0.02px;}
#t2k_193{left:881px;bottom:192px;}
#t2l_193{left:897px;bottom:192px;letter-spacing:0.01px;word-spacing:0.17px;}
#t2m_193{left:618px;bottom:168px;letter-spacing:0.11px;word-spacing:0.07px;}
#t2n_193{left:618px;bottom:145px;letter-spacing:0.12px;word-spacing:0.07px;}
#t2o_193{left:618px;bottom:122px;letter-spacing:0.12px;word-spacing:0.07px;}
#t2p_193{left:618px;bottom:99px;letter-spacing:0.21px;word-spacing:0.09px;}
#t2q_193{left:618px;bottom:75px;letter-spacing:0.13px;word-spacing:0.06px;}
#t2r_193{left:786px;bottom:75px;}
#t2s_193{left:802px;bottom:75px;letter-spacing:0.15px;word-spacing:0.03px;}
#t2t_193{left:618px;bottom:52px;letter-spacing:0.13px;word-spacing:0.05px;}
#t2u_193{left:23px;bottom:915px;letter-spacing:-0.14px;}

.s0_193{font-size:10px;font-family:ArialMT_5tg;color:#000;}
.s1_193{font-size:6px;font-family:ArialMT_5tg;color:#000;}
.s2_193{font-size:28px;font-family:Arial-BoldMT_5te;color:#000;}
.s3_193{font-size:17px;font-family:Arial-BoldMT_5te;color:#000;}
.s4_193{font-size:17px;font-family:ArialMT_5tg;color:#000;}
.s5_193{font-size:17px;font-family:Arial-ItalicMT_kb;color:#000;}
.s6_193{font-size:11px;font-family:ArialMT_5tg;color:#000;}
.s7_193{font-size:11px;font-family:Helvetica, Arial, sans-serif;color:#000;}
</style>
<style id="fonts193" type="text/css" >

@font-face {
	font-family: Arial-BoldMT_5te;
	src: url("fonts/Arial-BoldMT_5te.woff") format("woff");
}

@font-face {
	font-family: Arial-ItalicMT_kb;
	src: url("fonts/Arial-ItalicMT_kb.woff") format("woff");
}

@font-face {
	font-family: ArialMT_5tg;
	src: url("fonts/ArialMT_5tg.woff") format("woff");
}

</style>
<div id="pg193Overlay" style="width:100%; height:100%; position:absolute; z-index:1; background-color:rgba(0,0,0,0); -webkit-user-select: none;"></div>
<div id="pg193" style="-webkit-user-select: none;"><object width="1210" height="935" data="193/193.svg" type="image/svg+xml" id="pdf193" style="width:1210px; height:935px; z-index: 0;"></object></div>
<div class="text-container"><span id="t1_193" class="t s0_193">Version 4.2024 © 2024 National Comprehensive Cancer Network </span>
<span id="t2_193" class="t s1_193">© </span>
<span id="t3_193" class="t s0_193">(NCCN </span>
<span id="t4_193" class="t s1_193">© </span>
<span id="t5_193" class="t s0_193">), All rights reserved. NCCN Guidelines </span>
<span id="t6_193" class="t s1_193">® </span>
<span id="t7_193" class="t s0_193">and this illustration may not be reproduced in any form without the express written permission of NCCN. </span>
<span id="t8_193" class="t s2_193">NCCN Guidelines Version 4.2024 </span>
<span id="t9_193" class="t s2_193">Head and Neck Cancers </span>
<span id="ta_193" class="t s3_193">MS-52 </span>
<span id="tb_193" class="t s4_193">resected recurrence improves DFS, compared to patients receiving only </span>
<span id="tc_193" class="t s4_193">surgery (HR, 1.68; 95% CI, 1.13–2.50; </span><span id="td_193" class="t s5_193">P </span><span id="te_193" class="t s4_193">= .01). </span>
<span id="tf_193" class="t s6_193">652 </span>
<span id="tg_193" class="t s4_193">However, the toxicity </span>
<span id="th_193" class="t s4_193">of this regimen was considerable, with grade 3 of 4 acute toxicity </span>
<span id="ti_193" class="t s4_193">(mucositis/pharyngitis) in 28% of patients; however, results achieved </span>
<span id="tj_193" class="t s4_193">using the older techniques in this study may not apply to the current day. </span>
<span id="tk_193" class="t s4_193">SBRT with or without cetuximab following surgery for relapsed or </span>
<span id="tl_193" class="t s4_193">refractory disease has been investigated in an institutional report ( </span><span id="tm_193" class="t s5_193">N </span><span id="tn_193" class="t s4_193">= </span>
<span id="to_193" class="t s4_193">28). </span>
<span id="tp_193" class="t s6_193">260 </span>
<span id="tq_193" class="t s4_193">Advanced RT techniques should be used for reirradiation. A </span>
<span id="tr_193" class="t s4_193">retrospective review of 227 patients who were treated at an NCCN </span>
<span id="ts_193" class="t s4_193">Member Institution showed that IMRT-based reirradiation of the H&amp;N </span>
<span id="tt_193" class="t s4_193">may be associated with local control and improved survival rates, but </span>
<span id="tu_193" class="t s4_193">toxicity rates were considerable, with adverse events grade 3 or higher </span>
<span id="tv_193" class="t s4_193">occurring in 16% of patients at 2 years. </span>
<span id="tw_193" class="t s6_193">568,653 </span>
<span id="tx_193" class="t s4_193">Use of concurrent systemic </span>
<span id="ty_193" class="t s4_193">therapy may be associated with greater risk of toxicity. Rates for 1-year </span>
<span id="tz_193" class="t s4_193">local control, distant control, DFS, and OS were 51%, 90%, 49%, and </span>
<span id="t10_193" class="t s4_193">64%, respectively, and adverse events grade 3 or higher were rare. The </span>
<span id="t11_193" class="t s4_193">best outcomes for SBRT for reirradiation are in patients with smaller </span>
<span id="t12_193" class="t s4_193">tumors (&lt;25 cc) and no skin involvement. Intraoperative RT (IORT) and </span>
<span id="t13_193" class="t s4_193">brachytherapy may also be used for select patients at high-volume </span>
<span id="t14_193" class="t s4_193">centers. </span>
<span id="t15_193" class="t s6_193">654-656 </span>
<span id="t16_193" class="t s4_193">The decision to treat with reirradiation should take into account </span>
<span id="t17_193" class="t s4_193">comorbidity, the toxicity of previous treatment methods, organ </span>
<span id="t18_193" class="t s4_193">dysfunction, and the amount of time that has passed since previous </span>
<span id="t19_193" class="t s4_193">treatment. </span>
<span id="t1a_193" class="t s6_193">657-660 </span>
<span id="t1b_193" class="t s4_193">Treatment planning should at a minimum take spinal </span>
<span id="t1c_193" class="t s4_193">cord and laryngeal lifetime dose limits into account so that the safest </span>
<span id="t1d_193" class="t s4_193">maximum dose is delivered. </span>
<span id="t1e_193" class="t s6_193">657,661,662 </span>
<span id="t1f_193" class="t s4_193">PBT may be used for reirradiation </span>
<span id="t1g_193" class="t s4_193">when normal tissue constraints cannot be met by photon-based </span>
<span id="t1h_193" class="t s4_193">therapy. </span>
<span id="t1i_193" class="t s6_193">568,663-665 </span>
<span id="t1j_193" class="t s4_193">Retrospective studies show that PBT used for </span>
<span id="t1k_193" class="t s4_193">reirradiation may be associated with good outcomes (eg, 65%–84% OS, </span>
<span id="t1l_193" class="t s4_193">improved locoregional control, freedom from distant metastasis) and </span>
<span id="t1m_193" class="t s4_193">acceptable toxicity. </span>
<span id="t1n_193" class="t s6_193">247,663,664 </span>
<span id="t1o_193" class="t s4_193">However, in one retrospective study, three </span>
<span id="t1p_193" class="t s4_193">patients died (out of 60), possibly due to reirradiation-related effects. </span>
<span id="t1q_193" class="t s6_193">663 </span>
<span id="t1r_193" class="t s4_193">Dosing schedules that may be used for reirradiation are described in </span>
<span id="t1s_193" class="t s5_193">Radiation Techniques </span><span id="t1t_193" class="t s4_193">in the NCCN Guidelines for Head and Neck </span>
<span id="t1u_193" class="t s4_193">Cancers. Radiation volumes should usually include only volumes of known </span>
<span id="t1v_193" class="t s4_193">disease, to minimize the amount of tissue receiving high doses in </span>
<span id="t1w_193" class="t s4_193">previously irradiated regions. Therefore, prophylactic treatment (eg, </span>
<span id="t1x_193" class="t s4_193">elective nodal irradiation) is not routinely indicated. </span>
<span id="t1y_193" class="t s6_193">666 </span>
<span id="t1z_193" class="t s4_193">There are currently </span>
<span id="t20_193" class="t s4_193">knowledge gaps regarding the appropriate use of irradiation, and patients </span>
<span id="t21_193" class="t s4_193">should be encouraged to enroll in clinical trials. </span>
<span id="t22_193" class="t s6_193">568,657 </span>
<span id="t23_193" class="t s5_193">Disease That Has Progressed on or After Platinum Therapy </span>
<span id="t24_193" class="t s4_193">For failure of platinum-based therapy, options are listed in the Guidelines </span>
<span id="t25_193" class="t s4_193">(see </span><span id="t26_193" class="t s5_193">Principles of Systemic Therapy for Non-Nasopharyngeal Cancer: </span>
<span id="t27_193" class="t s5_193">Recurrent, Unresectable, or Metastatic </span><span id="t28_193" class="t s4_193">in the NCCN Guidelines for Head </span>
<span id="t29_193" class="t s4_193">and Neck Cancers). NGS genomic profiling may be considered to identify </span>
<span id="t2a_193" class="t s4_193">biomarkers for applicable targeted therapies. </span>
<span id="t2b_193" class="t s4_193">Nivolumab was assessed in a phase III RCT including 361 patients with </span>
<span id="t2c_193" class="t s4_193">recurrent SCCHN whose disease had progressed within 6 months </span>
<span id="t2d_193" class="t s4_193">following platinum-based chemotherapy. </span>
<span id="t2e_193" class="t s6_193">638 </span>
<span id="t2f_193" class="t s4_193">With a median follow-up of </span>
<span id="t2g_193" class="t s4_193">5.1 (range, 0–16.8) months, the OS was significantly greater in patients </span>
<span id="t2h_193" class="t s4_193">given nivolumab, compared to patients given standard second-line </span>
<span id="t2i_193" class="t s4_193">single-agent systemic therapy (methotrexate, docetaxel, or cetuximab) </span>
<span id="t2j_193" class="t s4_193">(HR, 0.70; 97.73% CI, 0.51–0.96; </span><span id="t2k_193" class="t s5_193">P </span><span id="t2l_193" class="t s4_193">= .01). One-year survival was also </span>
<span id="t2m_193" class="t s4_193">greater for patients who received nivolumab, relative to patients who </span>
<span id="t2n_193" class="t s4_193">received standard therapy (36.0% vs. 16.6%, respectively), and </span>
<span id="t2o_193" class="t s4_193">response rate was higher (13.3% vs. 5.8%, respectively), but median </span>
<span id="t2p_193" class="t s4_193">PFS was not significantly different between the two groups (2.0 vs. 2.3 </span>
<span id="t2q_193" class="t s4_193">months, respectively; </span><span id="t2r_193" class="t s5_193">P </span><span id="t2s_193" class="t s4_193">= .32). In prespecified exploratory analyses, the </span>
<span id="t2t_193" class="t s4_193">OS benefit in patients treated with nivolumab appeared to be confined to </span>
<span id="t2u_193" class="t s7_193">Printed by Fredd Merc on 8/29/2024 4:45:54 AM. For personal use only. Not approved for distribution. Copyright © 2024 National Comprehensive Cancer Network, Inc., All Rights Reserved. </span></div>

</div>
</body>
</html>
